CD7 aberrant expression led to a lineage switch at relapsed childhood acute pre-B lymphoblastic leukemia

Lanzkowsky P (2011) Manual of hematology and oncology. Elsevier, United States of America

Han X, Bueso-Ramos CE (2007) Precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma and acute biphenotypic leukemias. Am J Clin Pathol 127:528–544

Jaffe ES, Harris NL, Vardiman JW, Campo E, Arber DA (2010) Hematopathology. Saunders, Philadelphia, p 1072

Matutes E, Morilla R, Farahat N, Carbonell F, Swansbury J, Dyer M, Catovsky D (1997) Definition of acute biphenotypic leukemia. Haematologica 82:64–66

Henze G, Fengler R, Hartmann R, Kornhuber B, Janka-Schaub G, Niethammer D, Riehm H (1991) Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 78:1166–1172

Reiter A, Schrappe M, Ludwig W-D, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D (1994) Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122–3133

Van Wering E, Beishuizen A, Roeffen E, Van Der Linden-Schrever B, Verhoeven M, Hählen K, Hooijkaas H, Van Dongen J (1995) Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. Leukemia 9:1523–1533

Guglielmi C, Cordone I, Boecklin F, Masi S, Valentini T, Vegna M, Ferrari A, Testi A, Foa R (1997) Immunophenotype of adult and childhood acute lymphoblastic leukemia: changes at first relapse and clinico-prognostic implications. Leukemia 11:1501–1507

Rossi JG, Bernasconi AR, Alonso CN, Rubio PL, Gallego MS, Carrara CA, Guitter MR, Eberle SE, Cocce M, Zubizarreta PA (2012) Lineage switch in childhood acute leukemia: an unusual event with poor outcome. Am J Hematol 87:890–897

Raghavachar A, Thiel E, Bartram CR (1987) Analyses of phenotype and genotype in acute lymphoblastic leukemias at first presentation and in relapse. Blood 70:1079–1083

Moradi-Lakeh M, Esteghamati A (2013) National Immunization Program in Iran: whys and why nots. Hum Vaccin Immunother 9:112–114

Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, Ludwig W, Ritter J, Harbott J, Mann G (2010) Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24:265–284

Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE (1994) Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children’s Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 12:740–747

Park M, Koh KN, Kim BE, Im HJ, Jang S, Park CJ, Chi HS, Seo JJ (2011) Lineage switch at relapse of childhood acute leukemia: a report of four cases. J Korean Med Sci 26:829–831

Pui C-H, Raimondi SC, Behm FG, Ochs J, Furman WL, Bunin NJ, Ribeiro RC, Tinsley PA, Mirro J (1986) Shifts in blast cell phenotype and karyotype at relapse of childhood lymphoblastic leukemia [published erratum appears in Blood 1987 Mar; 69 (3): 996]. Blood 68:1306–1310

Abshire T, Buchanan G, Jackson J, Shuster J, Brock B, Head D, Behm F, Crist W, Link M, Borowitz M (1992) Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: a Pediatric Oncology Group study. Leukemia 6:357–362

Cruse JM, Lewis RE, Pierce S, Lam J, Tadros Y (2005) Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias. Exp Mol Pathol 79:39–41

Rausei-Mills V, Chang KL, Gaal KK, Weiss LM, Huang Q (2008) Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation. Am J Clin Pathol 129:624–629

Hussein S, Gill KZ, Sireci AN, Colovai AI, Small T, Emmons FN, Murty VV, Bhagat G, Alobeid B (2011) Aberrant T-cell antigen expression in B lymphoblastic leukaemia. Br J Haematol 155:449–456